Therefore, targeted approaches using JAK inhibitors and immune checkpoint blockade (anti-PD-1, anti-NKG2A) could be explored as future treatment options, with promising outcomes already documented in EATL, where chemotherapy and nivolumab-based immunotherapy have significantly improved progression and overall survival. This evidence concerns the gene KLRC1 and enteropathy-associated T-cell lymphoma.